Oncology

Glancing over at the changing development requirements for biosimilars in the US and Europe, the Chinese duo Chime Biologics and Beijing Libang Pharmaceutical are allying to develop a blinatumomab biosimilar rival to Amgen’s Blincyto.

Unified Patent Court ruling removes legal overhang on cabazitaxel generics already on the European market.

Industry warns healthcare infrastructure – not manufacturing – may be the real bottleneck as cell therapies eye mass-market diseases.

Phase III results for gamma secretase inhibitor varegacestat in the treatment of desmoid tumors appear superior on both efficacy and safety to Merck KGaA’s Ogsiveo (nirogacestat).

The companies presented 52-week data from the pivotal Phase III VERIFY study at the recent American Society of Hematology meeting, after releasing 32-week data earlier this year.

The drugmaker presented multiple posters of data for the recently reapproved BCMA-targeting antibody-drug conjugate at the just concluded ASH meeting.

In this episode of the In Vivo podcast, Kairos Pharma's chief scientific officer discusses developing therapies to reverse drug resistance in oncology, with ENV-105 showing promising Phase II results in resensitizing hormone-resistant prostate cancer.

Next-gen CAR-T therapies showcased at the American Society of Hematology's annual meeting promise improved efficacy and safety, with Novartis, Gilead, and Kelonia advancing pivotal trials and exploring in vivo approaches.

The company presented data on four patients as a late-breaking abstract at the American Society of Hematology meeting.

Data from the Phase III BRUIN CLL-313 trial presented at ASH showed clear superiority for the non-covalent BTK inhibitor as a single agent compared with bendamustine/rituximab.

The company presented Phase II results at ASH that lend support to an ongoing Phase III trial of the CELMoD drug in maintenance therapy of multiple myeloma.

AstraZeneca, Lilly, Novo Nordisk and Amgen all moved up in the rankings on the Scrip 100 leaderboard powered by impressive double-digit growth.